No Data
No Data
Shenzhen Kangtai Biological Products Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Kangtai Biotech: 2024 Semi-Annual Report Summary
Kangtai Biotech: 2024 Semi-Annual Report
Intense market competition combined with inventory reduction, Shenzhen Kangtai Biological Products' performance in the first half of the year has significantly declined | Interpretation of financial reports
①Affected by market competition and factors such as inventory reduction, the total revenue and net income attributable to the mother of shenzhen kangtai biological products declined in H1. ②The sales revenue of the business sector with the largest revenue contribution of the company decreased by more than 30% year-on-year. ③The accounts receivable of shenzhen kangtai biological products continued to climb, with a substantial decrease in cash flow.
Shenzhen Kangtai Biological Products (300601.SZ): The net income in the first half of the year was 0.165 billion yuan, a year-on-year decrease of 67.61%.
Shenzhen Kangtai Biological Products (300601.SZ) announced its semi-annual report for 2024, with operating revenue of 1.202 billion yuan for the reporting period, a year-on-year decrease of 30.54%; net income attributable to shareholders of the listed company of 0.165 billion yuan, a year-on-year decrease of 67.61%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 0.122 billion yuan, a year-on-year decrease of 71.66%; basic earnings per share of 0.15 yuan.
Shenzhen Kangtai Biological Products (300601.SZ) is currently in Phase I clinical trial for its adsorbed non-cellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae type b conjugate vaccine (pentavalent vaccine).
Shenzhen Kangtai Biological Products (300601.SZ) stated on the investor interaction platform on July 26 that the company's adsorbed combined vaccine for diphtheria, tetanus, pertussis, poliomyelitis and type b influenza (pentavalent vaccine) is currently in Phase I clinical trials. If the product development and registration progress meets the information disclosure standards, the company will fulfill information disclosure obligations in accordance with relevant laws and regulations.
No Data